公开(公告)号：US09845293B2

公开(公告)日：2017-12-19

申请号：US15515863

申请日：2016-02-23

Applicant: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.

Inventor： Simone Zaramella ,  Emiliano Rossi ,  Ottorino De Lucchi ,  Siro Serafini

IPC: C07D223/22 ,  C07D223/26

CPC classification number: C07D223/26 ,  B01J2231/643 ,  B01J2540/32 ,  C07D223/28

Abstract: Object of the present invention is an improved process for the preparation of Elsicarbazepine and Eslicarbazepine acetate by means of chiral Ruthenium catalysts.

公开(公告)号：US20160347680A1

公开(公告)日：2016-12-01

申请号：US15233089

申请日：2016-08-10

Applicant: CPI INNOVATION SERVICES LIMITED

Inventor： Ruksanna AHMAD ,  Jeremy COOPER ,  Isaac ODIASE

IPC: C07B63/00 ,  C07C51/43 ,  C07D213/82 ,  C07D239/42 ,  C07D473/12 ,  C07D223/26

CPC classification number: C07B63/00 ,  A61K31/194 ,  A61K31/455 ,  A61K31/505 ,  A61K31/522 ,  A61K31/55 ,  A61K31/60 ,  C07B2200/13 ,  C07C51/43 ,  C07D213/82 ,  C07D223/26 ,  C07D239/42 ,  C07D473/12

Abstract: The present invention relates to an active crystalline material, especially an active multicomponent crystalline material such as a salt or a cocrystal, which may be made by dispersing precursor components of the active crystalline material in a liquid medium which comprises an anti-solvent, maintaining the dispersion for a period during which the active crystalline material is formed, and, during said period, exposing the dispersion to a solvent, which solvent being present in the liquid medium in a minor proportion by weight thereof.

公开(公告)号：US09440925B2

公开(公告)日：2016-09-13

申请号：US14810766

申请日：2015-07-28

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Kyle Gee ,  Aimei Chen ,  Hee Chol Kang

IPC: G01N33/532 ,  C07K1/13 ,  C07C309/42 ,  C07D225/08 ,  C07D225/02 ,  C07K16/18 ,  C07D223/08 ,  C07D223/26

CPC classification number: C07D225/08 ,  C07C309/42 ,  C07C2603/36 ,  C07D223/08 ,  C07D223/26 ,  C07D225/02 ,  C07K1/13 ,  C07K16/18 ,  G01N33/532

Abstract: The present disclosure is directed to a reactive ester agent for conjugating a click-reactive group to a carrier molecule or solid support. The reactive ester agent has the general formula IA, wherein the variables R1, R2, R3, Ra and L are described throughout the application.

公开(公告)号：US20140107323A1

公开(公告)日：2014-04-17

申请号：US14006129

申请日：2012-03-22

Applicant: Kyle Gee ,  Aimei Chen ,  Hee Chol Kang

Inventor： Kyle Gee ,  Aimei Chen ,  Hee Chol Kang

IPC: C07C309/42 ,  C07D223/08 ,  C07K1/13 ,  C07D223/26

CPC classification number: C07D225/08 ,  C07C309/42 ,  C07C2603/36 ,  C07D223/08 ,  C07D223/26 ,  C07D225/02 ,  C07K1/13 ,  C07K16/18 ,  G01N33/532

Abstract: The present disclosure is directed to a reactive ester agent for conjugating a click-reactive group to a carrier molecule or solid support. The reactive ester agent has the general formula IA, wherein the variables R1, R2, R3, Ra and L are described throughout the application.

Abstract translation: 本公开涉及用于将点击反应性基团与载体分子或固体支持物缀合的反应性酯试剂。 反应性酯剂具有通式IA，其中在整个申请中描述了变量R1，R2，R3，Ra和L。

公开(公告)号：US08569000B2

公开(公告)日：2013-10-29

申请号：US13069181

申请日：2011-03-22

Applicant: Liuming Yu ,  Yaoming Liang ,  Hongbo Li

Inventor： Liuming Yu ,  Yaoming Liang ,  Hongbo Li

IPC: G01N33/53

CPC classification number: G01N33/9486 ,  C07D223/26 ,  C07K16/44

Abstract: The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.

Abstract translation: 本公开涉及针对卡马西平，用于产生抗体的免疫原和免疫测定试剂盒和使用抗体的方法的抗体。

公开(公告)号：US20130274248A1

公开(公告)日：2013-10-17

申请号：US13906424

申请日：2013-05-31

Applicant: National University Corporation Chiba University

Inventor： Kazuei Igarashi ,  Hiromitsu Takayama

IPC: C07D223/26 ,  C07D209/86 ,  C07D223/28 ,  C07C235/84

CPC classification number: C07D223/26 ,  A61K31/166 ,  A61K31/403 ,  A61K31/55 ,  C07C235/84 ,  C07D209/86 ,  C07D223/28

Abstract: [PROBLEMS] To provide a novel compound having NMDA receptor channel blocking activity, and also a pharmaceutical agent comprising the compound.[MEANS FOR SOLVING PROBLEMS] A pharmaceutical agent for the treatment or prevention of a disease caused by overexcitation of an NMDA receptor, which comprises a compound having NMDA receptor channel blocking activity and represented by the formula (1), a salt thereof, or a hydrate of the compound or the salt.

Abstract translation: [问题]提供具有NMDA受体通道阻断活性的新化合物，以及包含该化合物的药剂。 解决问题的手段用于治疗或预防由NMDA受体过度引起的疾病的药剂，其包含具有NMDA受体通道阻断活性并由式（1）表示的化合物，其盐或 化合物或盐的水合物。

公开(公告)号：US08435979B2

公开(公告)日：2013-05-07

申请号：US12643318

申请日：2009-12-21

Applicant: Jack L. Arbiser

Inventor： Jack L. Arbiser

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/55 ,  C07D223/18

CPC classification number: A61K31/55 ,  A61K9/127 ,  A61K31/136 ,  A61K31/14 ,  A61K31/353 ,  A61K31/404 ,  A61K31/422 ,  A61K31/428 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/54 ,  A61K31/553 ,  A61K31/662 ,  C07D215/26 ,  C07D215/46 ,  C07D223/26 ,  C07D223/28 ,  C07D263/32 ,  C07D275/06 ,  C07D279/28 ,  C07D311/36 ,  C07F9/4056 ,  C07F9/4059 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.

Abstract translation: 公开了化合物，包括该化合物的药物组合物，及其制备和使用方法。 化合物是三苯甲烷类似物。 化合物和组合物可用于治疗和/或预防多种癌症，包括耐药性癌症，炎性，退行性和血管性疾病以及寄生虫感染。 化合物是丙酰胺蓝的三苯甲烷类似物及其类似物，如本文所定义。 据信这些化合物通过抑制tNOX表达，ROS的作用和/或HIF2的产生起作用。 因此，这些化合物是用于各种癌症和其它疾病的新型治疗剂。

公开(公告)号：US20120322089A1

公开(公告)日：2012-12-20

申请号：US13525784

申请日：2012-06-18

Applicant: Elouard Benchikh ,  Andrew Philip Lowry ,  Ivan McConnell ,  Peter Stephen Fitzgerald

Inventor： Elouard Benchikh ,  Andrew Philip Lowry ,  Ivan McConnell ,  Peter Stephen Fitzgerald

IPC: G01N33/566 ,  C07K16/18 ,  C07K17/02

CPC classification number: C07K16/44 ,  C07D223/26 ,  C07D223/28 ,  C07D491/044 ,  G01N33/532 ,  G01N33/9473 ,  G01N33/9486

Abstract: The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.

Abstract translation: 本发明涉及卡马西平药物及其代谢物的检测和定量。 本发明由具有独特结合特性的新型多克隆抗体支持，其能够进行各种应用的免疫测定方法和试剂盒。

公开(公告)号：US20120244546A1

公开(公告)日：2012-09-27

申请号：US13069192

申请日：2011-03-22

Applicant: Liuming YU ,  Yaoming Liang ,  Hongbo Li

Inventor： Liuming YU ,  Yaoming Liang ,  Hongbo Li

IPC: G01N33/53 ,  G01N33/566 ,  C07K16/44 ,  C07D223/18 ,  C07K14/00

CPC classification number: G01N33/9486 ,  C07D223/26 ,  C07K16/44

Abstract: The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.

Abstract translation: 本公开涉及针对卡马西平，用于产生抗体的免疫原和免疫测定试剂盒和使用抗体的方法的抗体。

公开(公告)号：US20110263526A1

公开(公告)日：2011-10-27

申请号：US13092245

申请日：2011-04-22

Applicant: Apparao SATYAM

Inventor： Apparao SATYAM

IPC: A61K31/7072 ,  A61K31/58 ,  A61K31/55 ,  A61K31/495 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/403 ,  A61K31/404 ,  A61K31/40 ,  A61K31/265 ,  C07H19/06 ,  C07J71/00 ,  C07D223/26 ,  C07D295/14 ,  C07D401/12 ,  C07D213/80 ,  C07D209/52 ,  C07D209/26 ,  C07D207/34 ,  C07D493/04 ,  C07C323/56 ,  A61P25/18 ,  C07C69/96 ,  C07C319/22 ,  C07C68/02 ,  A61P29/00 ,  A61P9/00 ,  A61P37/08 ,  A61P35/00 ,  A61P25/24 ,  A61P25/08 ,  A61P31/04 ,  A61P31/12 ,  A61P31/10 ,  A61P33/06 ,  A61P3/10 ,  A61P1/04 ,  A61P39/06 ,  A61P3/02 ,  A61P9/06 ,  A61P9/02 ,  A61P9/08 ,  A61P11/08 ,  A61K31/621

CPC classification number: C07C203/04 ,  C07C229/42 ,  C07C233/25 ,  C07C233/63 ,  C07C317/18 ,  C07C323/12 ,  C07C2601/14 ,  C07D207/27 ,  C07D207/34 ,  C07D209/28 ,  C07D209/52 ,  C07D213/30 ,  C07D213/80 ,  C07D223/26 ,  C07D223/28 ,  C07D233/91 ,  C07D295/088 ,  C07D305/14 ,  C07D307/20 ,  C07D401/12 ,  C07D403/10 ,  C07D493/04 ,  C07J41/005 ,  C07J71/0031

Abstract: The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

Abstract translation: 本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在本文中表示为式（I）化合物，其中药物或治疗剂含有一个或多个独立地选自羧酸，氨基，羟基的官能团 和巯基。 本发明还涉及制备一氧化氮释放前体药物（式（I）化合物）的方法，含有它们的药物组合物和使用前药的方法。